Davide Bolignano1, Carmine Zoccali. 1. CNR-IBIM, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension of Reggio Calabria, Reggio Calabria, Italy.
Abstract
PURPOSE OF REVIEW: This review aims to analyze the relationships between arginine vasopressin (AVP) and chronic kidney disease (CKD) and to define the potential of vasopressin receptor antagonists beyond the treatment of water metabolism disorders. RECENT FINDINGS: Experimental studies in rat and observational studies in humans suggest that AVP may play a role in the genesis and exacerbation of renal damage and chronic renal insufficiency. SUMMARY: A sustained stimulation of vasopressin receptors induces intrarenal renin-angiotensin system activation, podocyte alterations, glomerular hyperfiltration and hypertrophy eventuating in proteinuria and kidney damage. Furthermore, AVP directly stimulates contraction and proliferation of mesangial cells and accumulation of extracellular matrix and glomerulosclerosis. Whether a chronic increase in water intake (determining a reduction in endogenous AVP levels) and/or the administration of vasopressin receptor antagonists are useful for the prevention and treatment of CKD remains to be tested in clinical trials.
PURPOSE OF REVIEW: This review aims to analyze the relationships between arginine vasopressin (AVP) and chronic kidney disease (CKD) and to define the potential of vasopressin receptor antagonists beyond the treatment of water metabolism disorders. RECENT FINDINGS: Experimental studies in rat and observational studies in humans suggest that AVP may play a role in the genesis and exacerbation of renal damage and chronic renal insufficiency. SUMMARY: A sustained stimulation of vasopressin receptors induces intrarenal renin-angiotensin system activation, podocyte alterations, glomerular hyperfiltration and hypertrophy eventuating in proteinuria and kidney damage. Furthermore, AVP directly stimulates contraction and proliferation of mesangial cells and accumulation of extracellular matrix and glomerulosclerosis. Whether a chronic increase in water intake (determining a reduction in endogenous AVP levels) and/or the administration of vasopressin receptor antagonists are useful for the prevention and treatment of CKD remains to be tested in clinical trials.
Authors: W E Boertien; I J Riphagen; I Drion; A Alkhalaf; S J L Bakker; K H Groenier; J Struck; P E de Jong; H J G Bilo; N Kleefstra; R T Gansevoort Journal: Diabetologia Date: 2013-04-28 Impact factor: 10.122
Authors: Richard J Johnson; Bernardo Rodriguez-Iturbe; Carlos Roncal-Jimenez; Miguel A Lanaspa; Takuji Ishimoto; Takahiko Nakagawa; Ricardo Correa-Rotter; Catharina Wesseling; Lise Bankir; Laura G Sanchez-Lozada Journal: Nat Rev Nephrol Date: 2014-05-06 Impact factor: 28.314
Authors: Carlos A Roncal Jimenez; Takuji Ishimoto; Miguel A Lanaspa; Christopher J Rivard; Takahiko Nakagawa; A Ahsan Ejaz; Christina Cicerchi; Shinichiro Inaba; MyPhuong Le; Makoto Miyazaki; Jason Glaser; Ricardo Correa-Rotter; Marvin A González; Aurora Aragón; Catharina Wesseling; Laura G Sánchez-Lozada; Richard J Johnson Journal: Kidney Int Date: 2013-12-11 Impact factor: 10.612
Authors: Ineke J Riphagen; Wendy E Boertien; Alaa Alkhalaf; Nanne Kleefstra; Ron T Gansevoort; Klaas H Groenier; Kornelis J J van Hateren; Joachim Struck; Gerjan Navis; Henk J G Bilo; Stephan J L Bakker Journal: Diabetes Care Date: 2013-06-11 Impact factor: 19.112
Authors: Jessica M Sontrop; Shi-Han Huang; Amit X Garg; Louise Moist; Andrew A House; Kerri Gallo; William F Clark Journal: BMJ Open Date: 2015-11-24 Impact factor: 2.692